ReviewCureus2022
A Systematic Review of Antibiotic Resistance Trends and Treatment Options for Hospital-Acquired Multidrug-Resistant Infections.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prevalence of Antimicrobial Resistance in Klebsiella pneumoniae in the South African Populations: A Systematic Review and Meta-Analysis of Surveillance Studies.MicrobiologyOpen · 2025Pooled it
- Antibiotic Consumption Patterns in Three Romanian Hospitals: A Five-Year Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Beyond Antibiotics: The Role of Antimicrobial Polymers in Modern Therapeutics.Pharmaceutics · 2026Review
- Surveillance of bacterial colonization and infection in high-risk neonates admitted to tertiary referral hospital in Indonesia.BMC infectious diseases · 2026Article
- Phenotypic and genomic profiling of multidrug-resistant Escherichia coli and Klebsiella pneumoniae isolated from Intensive Care Unit patients in Kenya.BMC microbiology · 2026Article
- The Difluoroboranyl-Fluoroquinolone Derivative "7a" Inhibits Bacterial DNA Gyrase and Exhibits Potent Activity Against Ciprofloxacin-ResistantMolecules (Basel, Switzerland) · 2026Article
- Disinfectant-induced bacterial resistance and antibiotic cross-resistance-mechanisms and clinical relevance.Clinical and experimental medicine · 2025Review
- Pathogenic bacteria enriched in the oral microbiota might be associated with recurrent pulmonary infections in elderly individuals.Aging clinical and experimental research · 2025Article
- From Cure to Crisis: Understanding the Evolution of Antibiotic-Resistant Bacteria in Human Microbiota.Biomolecules · 2025Review
- Comparative analysis of antibiotic resistance and biofilm formation inFEMS microbes · 2025Article
- The challenge of antimicrobial resistance (AMR): current status and future prospects.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Presepsin Does Not Predict Risk of Death in Sepsis Patients Admitted to the Intensive Care Unit: A Prospective Single-Center Study.Biomedicines · 2024Article
- Resistome in a changing environment: Hotspots and vectors of spreading with a focus on the Russian-Ukrainian War.Heliyon · 2024Review
- Risk factors of multidrug-resistant organisms neonatal sepsis in Surabaya tertiary referral hospital: a single-center study.BMC pediatrics · 2024Article
- Nanotechnology in the Diagnosis and Treatment of Antibiotic-Resistant Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Comparative Analysis of Microbial Species and Multidrug Resistance Patterns in Acute Cholangitis Patients with Cholecystectomy: A Single-Center Study.Diseases (Basel, Switzerland) · 2024Article
- Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance.Frontiers in microbiology · 2024Review
- The Most Common Multi-Drug Resistant Bacteria Associated with Hospital Infections, in Urmia, Iran.Iranian journal of pathology · 2024Article
- Potential of Flavonoids as Promising Phytotherapeutic Agents to Combat Multidrug-Resistant Infections.Current pharmaceutical biotechnology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a major public health challenge described by the World Health Organization as one of the top 10 public health challenges worldwide. Drug-resistant microbes contribute significantly to morbidity and mortality in the hospital, especially in the critical care unit. The primary etiology of increasing antibiotic resistance is inappropriate and excessive use of antibiotics. The alarming rise of drug-resistant microbes worldwide threatens to erode our ability to treat infections with our current armamentarium of antibiotics. Unfortunately, the pace of development of new antibiotics by the pharmaceutical industry has not kept up with rising resistance to expand our options to treat microbial infections. The costs of antibiotic resistance include death and disability, extended hospital stays due to prolonged sickness, need for expensive therapies, rising healthcare expenditure, reduced productivity from time out of the workforce, and rising penury. This review sums up the common mechanisms, trends, and treatment options for hospital-acquired multidrug-resistant microbes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.